Oslo, Norway, 12 August 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its executive management team will participate in the following upcoming investor conferences:
|
Wedbush Life Sciences Management Access Conference
|
|
Date: 13-14 August 2013
|
|
Participants:
|
| |
Andrew Kay (President & CEO)
|
| |
Oystein Soug (CFO)
|
| |
Mike Booth (SVP, Communications)
|
|
Presentation date: Tuesday 13 August 2013
|
|
Venue: New York City, NY, USA
|
|
Morgan Stanley Global Healthcare Conference
|
|
Date: 9-11 September 2013
|
|
Participants:
|
| |
Andrew Kay (President & CEO)
|
| |
Oystein Soug (CFO)
|
| |
Mike Booth (SVP, Communications)
|
|
Presentation date: Monday 9 September 2013
|
|
Venue: New York City, NY, USA
|
|
J.P. Morgan Cazenove London Small/Mid-Cap 1x1 Conference
|
|
Date: 11-12 September 2013
|
|
Participants:
|
| |
Oystein Soug (CFO)
|
| |
Mike Booth (SVP, Communications)
|
|
Venue: London, UK
|
|
Bank of America Merrill Lynch Global Healthcare Conference
|
|
Date: 11-13 September 2013
|
|
Participants:
|
| |
Oystein Soug (CFO)
|
| |
Mike Booth (SVP, Communications)
|
|
Presentation date: Friday 13 September 2013
|
|
Venue: London, UK
|
Presentations, where applicable, will be available to download at www.algeta.com following these events.
###
For further information, please contact:
|
Mike Booth / Renate Birkeli
|
+47 23 00 67 32
|
|
Communications & Corporate Affairs
| ir@algeta.com |
| |
|
Media enquiries: | |
|
Mark Swallow
|
+44 207 638 9571
|
|
Citigate Dewe Rogerson
| mark.swallow@citigatedr.co.uk |
| |
|
Knut Ekern
|
+47 22 04 82 00
|
|
Gambit Hill & Knowlton
| knut.ekern@hkstrategies.com |
| |
|
Kari Watson
|
+1 781 235 3060
|
|
MacDougall Biomedical Communications
| kwatson@macbiocom.com |
| |
|
US investor enquiries: | |
|
Tricia Swanson
|
+1 646 378 2953
|
|
The Trout Group
| tswanson@troutgroup.com |
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
distributed by
 | |
ALGETA ASA 
By 
